TY - JOUR
T1 - Determining the Safety and Efficacy of Enhanced Recovery Protocols in Major Oncologic Surgery
T2 - An Institutional NSQIP Analysis
AU - Marcus, Rebecca K.
AU - Lillemoe, Heather A.
AU - Rice, David C.
AU - Mena, Gabriel
AU - Bednarski, Brian K.
AU - Speer, Barbra B.
AU - Ramirez, Pedro T.
AU - Lasala, Javier D.
AU - Navai, Neema
AU - Williams, Wendell H.
AU - Kim, Bradford J.
AU - Voss, Rachel K.
AU - Gottumukkala, Vijaya N.
AU - Aloia, Thomas A.
N1 - Funding Information:
FUNDING Drs. Rebecca Marcus and Heather Lillemoe are supported by National Institutes of Health grant T32CA009599 and the MD Anderson Cancer Center support grant P30CA016672.
Publisher Copyright:
© 2019, Society of Surgical Oncology.
PY - 2019/3/15
Y1 - 2019/3/15
N2 - Background: Enhanced-recovery (ER) protocols are increasingly being utilized in surgical practice. Outside of colorectal surgery, however, their feasibility, safety, and efficacy in major oncologic surgery have not been proven. This study compared patient outcomes before and after multispecialty implementation of ER protocols at a large, comprehensive cancer center. Methods: Surgical cases performed from 2011 to 2016 and captured by an institutional NSQIP database were reviewed. Following exclusion of outpatient and emergent surgeries, 2747 cases were included in the analyses. Cases were stratified by presence or absence of ER compliance, defined by preoperative patient education and electronic medical record order set-driven opioid-sparing analgesia, goal-directed fluid therapy, and early postoperative diet advancement and ambulation. Results: Approximately half of patients were treated on ER protocols (46%) and the remaining on traditional postoperative (TP) protocols (54%). Treatment on an ER protocol was associated with decreased overall complication rates (20% vs. 33%, p < 0.0001), severe complication rates (7.4% vs. 10%, p = 0.010), and median hospital length of stay (4 vs. 5 days, p < 0.0001). There was no change in readmission rates (ER vs. TP, 8.6% vs. 9.0%, p = 0.701). Subanalyses of high magnitude cases and specialty-specific outcomes consistently demonstrated improved outcomes with ER protocol adherence, including decreased opioid use. Conclusions: This assessment of a large-scale ER implementation in multispecialty major oncologic surgery indicates its feasibility, safety, and efficacy. Future efforts should be directed toward defining the long-term oncologic benefits of these protocols.
AB - Background: Enhanced-recovery (ER) protocols are increasingly being utilized in surgical practice. Outside of colorectal surgery, however, their feasibility, safety, and efficacy in major oncologic surgery have not been proven. This study compared patient outcomes before and after multispecialty implementation of ER protocols at a large, comprehensive cancer center. Methods: Surgical cases performed from 2011 to 2016 and captured by an institutional NSQIP database were reviewed. Following exclusion of outpatient and emergent surgeries, 2747 cases were included in the analyses. Cases were stratified by presence or absence of ER compliance, defined by preoperative patient education and electronic medical record order set-driven opioid-sparing analgesia, goal-directed fluid therapy, and early postoperative diet advancement and ambulation. Results: Approximately half of patients were treated on ER protocols (46%) and the remaining on traditional postoperative (TP) protocols (54%). Treatment on an ER protocol was associated with decreased overall complication rates (20% vs. 33%, p < 0.0001), severe complication rates (7.4% vs. 10%, p = 0.010), and median hospital length of stay (4 vs. 5 days, p < 0.0001). There was no change in readmission rates (ER vs. TP, 8.6% vs. 9.0%, p = 0.701). Subanalyses of high magnitude cases and specialty-specific outcomes consistently demonstrated improved outcomes with ER protocol adherence, including decreased opioid use. Conclusions: This assessment of a large-scale ER implementation in multispecialty major oncologic surgery indicates its feasibility, safety, and efficacy. Future efforts should be directed toward defining the long-term oncologic benefits of these protocols.
UR - http://www.scopus.com/inward/record.url?scp=85059685433&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059685433&partnerID=8YFLogxK
U2 - 10.1245/s10434-018-07150-5
DO - 10.1245/s10434-018-07150-5
M3 - Article
C2 - 30627879
AN - SCOPUS:85059685433
SN - 1068-9265
VL - 26
SP - 782
EP - 790
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 3
ER -